Outpatient administration of naxitamab in combination with granulocyte-macrophage colony-stimulating factor in patients with refractory and/or relapsed high-risk neuroblastoma: Management of adverse events.
Jaume MoraGodfrey Chi Fung ChanDaniel A MorgensternKarsten NysomMelissa K BearKaren TornøeBrian H KushnerPublished in: Cancer reports (Hoboken, N.J.) (2022)
This article highlights the protocol-based recommendations for the management of acute AEs associated with outpatient naxitamab treatment in Trial 201. The authors recommend close monitoring and timely implementation of measures to ensure that patients can remain on treatment and obtain maximum clinical benefit from naxitamab therapy.
Keyphrases
- end stage renal disease
- randomized controlled trial
- healthcare
- chronic kidney disease
- acute myeloid leukemia
- clinical trial
- newly diagnosed
- acute lymphoblastic leukemia
- study protocol
- combination therapy
- stem cells
- prognostic factors
- peritoneal dialysis
- respiratory failure
- intensive care unit
- peripheral blood
- phase ii
- extracorporeal membrane oxygenation
- open label
- clinical practice
- recombinant human